Analysts Set Inspire Medical Systems, Inc. (NYSE:INSP) Price Target at $81.84

Inspire Medical Systems, Inc. (NYSE:INSP) has earned an average rating of “Hold” from the twenty analysts that are presently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $81.0526.

INSP has been the topic of several research reports. Stifel Nicolaus decreased their price target on shares of Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. JPMorgan Chase & Co. decreased their price target on shares of Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 5th. Zacks Research downgraded shares of Inspire Medical Systems from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 13th. Truist Financial cut their price objective on shares of Inspire Medical Systems from $64.00 to $50.00 and set a “hold” rating for the company in a research report on Tuesday, May 5th. Finally, Mizuho cut their price objective on shares of Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a research report on Tuesday, May 5th.

Institutional Investors Weigh In On Inspire Medical Systems

Hedge funds and other institutional investors have recently bought and sold shares of the company. State of New Jersey Common Pension Fund D increased its position in Inspire Medical Systems by 79.9% during the third quarter. State of New Jersey Common Pension Fund D now owns 23,216 shares of the company’s stock worth $1,723,000 after purchasing an additional 10,311 shares during the last quarter. Regal Partners Ltd acquired a new stake in Inspire Medical Systems during the third quarter worth about $7,547,000. Rheos Capital Works Inc. increased its position in Inspire Medical Systems by 124.0% during the fourth quarter. Rheos Capital Works Inc. now owns 117,400 shares of the company’s stock worth $10,828,000 after purchasing an additional 65,000 shares during the last quarter. Aberdeen Group plc increased its position in Inspire Medical Systems by 16.3% during the fourth quarter. Aberdeen Group plc now owns 460,901 shares of the company’s stock worth $42,509,000 after purchasing an additional 64,561 shares during the last quarter. Finally, Banque Pictet & Cie SA increased its position in Inspire Medical Systems by 797.5% during the fourth quarter. Banque Pictet & Cie SA now owns 24,474 shares of the company’s stock worth $2,257,000 after purchasing an additional 21,747 shares during the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Inspire Medical Systems Trading Down 1.6%

NYSE:INSP opened at $44.98 on Tuesday. The company’s 50-day moving average price is $45.29 and its 200-day moving average price is $64.44. The company has a market cap of $1.30 billion, a P/E ratio of 10.02, a P/E/G ratio of 4.63 and a beta of 0.73. Inspire Medical Systems has a twelve month low of $38.91 and a twelve month high of $147.03.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.38. The firm had revenue of $204.58 million for the quarter, compared to the consensus estimate of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The company’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same period last year, the firm posted $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, analysts expect that Inspire Medical Systems will post 0.93 earnings per share for the current year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.